Get all your news in one place.
100's of premium titles.
One app.
Start reading
Barchart
Barchart
Kritika Sarmah

Biogen's Quarterly Earnings Preview: What You Need to Know

Biogen Inc. (BIIB), headquartered in Cambridge, Massachusetts, specializes in discovering, developing, manufacturing, and delivering therapies for neurological and neurodegenerative diseases. Valued at a market capitalization of $20.6 billion, the company's portfolio includes treatments for conditions such as multiple sclerosis, non-Hodgkin's lymphoma, rheumatoid arthritis, Crohn's disease, and psoriasis. BIIB is expected to announce its fiscal fourth-quarter earnings for 2024 before the market opens on Tuesday, Feb. 11.

Ahead of the event, analysts expect BIIB to report a profit of $3.43 per share on a diluted basis, up 16.3% from $2.95 per share in the year-ago quarter. The company beat the consensus estimates in three of the last four quarters while missing the forecast on another occasion. 

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.